Hexarelin
Hexarelin is a ghrelin-receptor agonist with a twist: unlike most growth hormone secretagogues, it also binds a second, entirely unrelated receptor — pushing a large share of its research toward cardioprotection rather than GH release alone.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is Hexarelin?
Hexarelin is a ghrelin-receptor (GHSR1a) agonist, the same receptor class studied for Ipamorelin. What sets it apart is a second binding target: CD36, a receptor unrelated to growth hormone release. This dual-receptor profile has pushed Hexarelin research in a different direction from most GH secretagogues — alongside GH-secretagogue pharmacology, a substantial share of its literature examines GH-independent cardioprotective effects mediated through CD36, including protection of cardiomyocytes from ischemia/reperfusion injury.
Research Focus
Hexarelin sits alongside CJC-1295, Ipamorelin, and Tesamorelin in growth-hormone-axis research, but its cardioprotective angle is unique among GH-axis compounds referenced on this site. See our GHRH & Growth Hormone research overview for how it fits alongside KYIN's stocked GH-axis peptides, or how Sermorelin and Anamorelin compare as other non-stocked compounds in this category, or the now-stocked GHRP-6.
Clinical & Preclinical Trial Data
Human GH-response data (Ghigo et al.) found that hexarelin's GH-releasing effect is strongly age- and pubertal-status-dependent: it produced a robust response in pubertal children and adults, but a substantially blunted response in prepubertal children and elderly subjects. In a separate comparison of 15 children and 4 adults with GH deficiency, hexarelin produced a GH response similar to or exceeding that seen with GHRH itself.
Its cardioprotective research is entirely preclinical — a rat ischemia/reperfusion model found hexarelin improved cardiomyocyte survival and downregulated IL-1β signaling through cardiac GHSR1a receptors, independent of GH release. No completed human clinical trial for a specific therapeutic indication has been located; hexarelin is used mainly as a research and provocative-testing tool rather than an approved drug.
Availability
Hexarelin is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
Hexarelin questions
What is Hexarelin?
Hexarelin is a ghrelin-receptor (GHSR1a) agonist, like Ipamorelin, but it additionally binds CD36, a second receptor unrelated to growth hormone release. This dual-receptor profile has pushed a substantial share of its research toward GH-independent cardioprotective effects mediated through CD36.
Does Hexarelin's growth hormone response vary by age?
Yes. Human data found hexarelin's GH-releasing effect is strongly age- and pubertal-status-dependent — a robust response in pubertal children and adults, but a substantially blunted response in prepubertal children and elderly subjects.
Is Hexarelin's cardioprotective research in humans or animals?
Entirely preclinical. A rat ischemia/reperfusion model found hexarelin improved cardiomyocyte survival and downregulated IL-1β signaling through cardiac GHSR1a receptors, independent of GH release. No completed human clinical trial for a specific therapeutic indication has been located.
Does KYIN Peptides sell Hexarelin?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing Hexarelin?
Contact us and we'll help you source it, or browse our stocked GH-axis peptides.